Pure Global

The DNA testing kit for the detection and differentiation of 14 types of high-risk human papilloma virus (HPV) - Vietnam Registration 230000348/PCBB-BYT

Access comprehensive regulatory information for The DNA testing kit for the detection and differentiation of 14 types of high-risk human papilloma virus (HPV) in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loแบกi B medical device is registered under number 230000348/PCBB-BYT and manufactured by OSANG Healthcare Co., Ltd..

This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
300,000+ Devices
230000348/PCBB-BYT
Registration Details
Vietnam MOH Registration: 230000348/PCBB-BYT
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Device Details

The DNA testing kit for the detection and differentiation of 14 types of high-risk human papilloma virus (HPV)
VN: Bแป™ xรฉt nghiแป‡m phรกt hiแป‡n vร  phรขn biแป‡t DNA cแปงa 14 loแบกi virus human papilloma (HPV) nguy cฦก cao
Risk Class TTBYT Loแบกi B

Registration Details

230000348/PCBB-BYT

000.00.04.G18-231014-0002

High Risk HPV ELITe Panel

Company Information

Technical Details

The "High Risk HPV ELITe Panel" product is a multiplex nucleic acid amplification real-time test designed to qualitatively detect and differentiate the DNA of 14 types of high-risk human papillomavirus (HPV) that cause cervical cancer in samples of DNA extracted from cervical cytology samples. The test specifically identifies types HPV16 and HPV18 and simultaneously detects the remaining high-risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). This product is intended to be used as an in vitro diagnostic tool to support the diagnosis of HPV infection, in conjunction with the patient's clinical data and other laboratory test results.

Dates and Status

Oct 14, 2023